Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumour
responses through a dual mechanism of action that is dependent on selective tumour cell …

Newcastle disease (ND) is one of the highly pathogenic viral diseases of avian species. ND
is economically significant because of the huge mortality and morbidity associated with it …

The prognosis of malignant gliomas remains poor, with median survival fewer than 20
months and a 5-year survival rate merely 5%. Their primary location in the central nervous …

Background Due to the lack of protective immunity of humans towards the newly emerged
SARS-CoV-2, this virus has caused a massive pandemic across the world resulting in …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing
with a poor prognosis and treatment prospective. Despite the aggressive standard care …

The oncolytic features of several naturally oncolytic viruses have been shown on
Glioblastoma Multiforme cell lines and in xenotransplant models. However, orthotopic …

Oncolytic viral therapy has been accepted as a standard immunotherapy since talimogene
laherparepvec (T-VEC, Imlygic®) was approved by the Food and Drug Administration (FDA) …